Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial

Main Article Content

Jan Gutermuth
Department of Dermatology, Universitair Ziekenhuis Brussel and Vrije Universiteit Brussel, Brussels, Belgium

Andrew Pink
St. John's Institute of Dermatology, Guy’s and St. Thomas’ Hospitals, London, UK

Margitta Worm
Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergy, Charité –Universitätsmedizin Berlin, Berlin, Germany

Lise Soldbro
LEO Pharma A/S, Ballerup, Denmark

Thomas Mark
LEO Pharma A/S, Ballerup, Denmark

Joshua Corriveau
LEO Pharma

Christian Bjeeregard Oland
LEO Pharma A/S, Ballerup, Denmark

Stephan Weidinger
6Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

Keywords

tralokinumab, atopic dermatitis, efficacy, safety, dupilumab

Abstract

N/A

References

1. Weidinger S, Novak N. Lancet. 2016;387:1109–22;

2. Eckert L, et al. J Am Acad Dermatol. 2017;77:274–9.e273;

3. Silverberg JI, et al. Ann
Allergy Asthma Immunol. 2018;121:340–7;

4. Dalgard FJ, et al. J Invest Dermatol. 2015;135:984–91;

5. Bieber T. Allergy. 2020;75:54–62;

6. Tsoi LC, et al. J Invest Dermatol. 2019;139:1480–9;

7. Popovic B, et al. J Mol Biol. 2017;429:208–19;

8. Simpson et al. Safety of specifically targeting interleukin 13 with tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomised, doubleblind, placebo-controlled Phase 3 and Phase 2 trials. Poster presented at: 29th EADV Congress; 29-31 October 2020; Virtual.

Article Sidebar

Poster PDF
Published
Nov 5, 2021
DOI https://doi.org/10.25251/skin.5.supp.60

Article Details

How to Cite
Gutermuth, J., Pink, A. ., Worm, M., Soldbro, L., Mark, T., Corriveau, J., Bjeeregard Oland, C., & Weidinger, S. (2021). Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial. SKIN The Journal of Cutaneous Medicine, 5(6), s60. https://doi.org/10.25251/skin.5.supp.60
Issue
Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>